Literature DB >> 9428548

Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration.

G Capellier1, C Cornette, A Boillot, C Guinchard, T Jacques, G Blasco, F Barale.   

Abstract

OBJECTIVE: Continuous hemofiltration is now widely used in the intensive care unit. Our study aimed to assess the removal of piperacillin under continuous hemofiltration and to define a suitable dosage regimen of administration.
DESIGN: Prospective study of blood and ultrafiltrate concentrations of piperacillin to assess the pharmacokinetics of the antibiotic.
SETTING: The medical intensive care unit of a teaching hospital. PATIENTS: Ten patients were included in the study. Six patients were receiving their first dose of piperacillin (group 1) and four had already been treated for 2 to 6 days (group 2). The mean Simplified Acute Physiology II score was 74 +/- 6 (SEM), and the number of organ failures was 3.6 +/- 0.3 (range 3 to 5). Renal failure was related to septic shock in seven patients and to cardiogenic shock in three patients. Seven patients were anuric. Hepatic dysfunction was present in four of the ten patients.
INTERVENTIONS: Patients were treated with continuous venovenous hemofiltration using a hollow polysulfone capillary fiber. Piperacillin (4 g) was injected intravenously over 20 mins. Arterial blood and ultrafiltrate were sampled immediately before the injection and then every hour until 8 hrs after injection time. Piperacillin concentrations were assayed using high performance liquid chromatography.
MEASUREMENTS AND MAIN RESULTS: In group 1, the mean serum peak concentration of piperacillin was in the normal range (125 +/- 21 mg/L), but trough values were higher (48 +/- 8 mg/L) than in normal subjects. In group 2, trough values before the injection were increased in all patients (188 +/- 71 mg/L). At T1, blood peak concentration reached 470 +/- 127 mg/L. A small amount of piperacillin was retrieved from the ultrafiltrate. The elimination half-life was 5.1 +/- 1.4 and 4.8 +/- 1.4 hrs in groups 1 and 2, respectively.
CONCLUSIONS: Piperacillin was not removed to a significant extent during continuous hemofiltration. Further, in the intensive care unit, patients in shock with multiple organ failure such as liver failure might behave differently from patients with stable end-stage renal disease. A 4-g dose of piperacillin twice a day is recommended in such patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428548     DOI: 10.1097/00003246-199801000-00021

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

3.  A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.

Authors:  Sanjoy Ketan Paul; Jason A Roberts; Jeffrey Lipman; Renae Deans; Mayukh Samanta
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 4.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

Review 5.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

7.  A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.

Authors:  Darren M Roberts; Xin Liu; Jason A Roberts; Priya Nair; Louise Cole; Michael S Roberts; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care       Date:  2015-03-13       Impact factor: 9.097

Review 8.  Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.

Authors:  Marta Ulldemolins; Sergi Vaquer; Mireia Llauradó-Serra; Caridad Pontes; Gonzalo Calvo; Dolors Soy; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

Review 9.  Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.

Authors:  Daniel J Selig; Jesse P DeLuca; Kevin K Chung; Kaitlin A Pruskowski; Jeffrey R Livezey; Robert J Nadeau; Elaine D Por; Kevin S Akers
Journal:  J Clin Pharm Ther       Date:  2022-03-29       Impact factor: 2.145

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.